(Alliance News) - Allergy Therapeutics PLC - Sussex-based biotechnology firm focused on allergy vaccines - Says the secondary endpoint results from an ex-vivo biomarker study VLP001 which evaluated the group's novel virus-like particle based peanut allergy vaccine candidate, VLP Peanut. Says secondary endpoint results demonstrated a reduced IgE binding capacity to B cells of VLP Peanut suggesting a promising safety profile with reduced potency to induce allergic reactions. Further, the results provide a strong indication for the products' efficacy potential, promoting a class switch from the allergic Th2 pathway to the more tolerogenic Th1 pathway.
Chief Executive Officer Manuel Llobet says: "We are pleased to see such encouraging secondary endpoint data, following the primary endpoint that we announced just a few weeks ago. These ex-vivo data, using human cells, clearly suggest that the vaccine candidate does not only have hypoallergic potential but also has the ability to induce a protective immune-response upon administration. This is a vital step in our journey to provide a safe and sustained effective treatment solution to those affected by peanut allergy; we look forward to progressing with the clinical programme and to initiate the Protect study in 2022."
Current stock price: 35.88 pence
Year-to-date change: more than doubled
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Allergy Thera. (AGY)